Bharat Biotech has successfully completed the third phase of the country's first nasal covid vaccine BBV-154.
Nasal Corona Vaccine: On the occasion of Independence Day, India has got great success in the war against Corona. Bharat Biotech has successfully completed the third phase of the country's first nasal covid vaccine BBV-154. With this, now this vaccine can be given as a booster dose.
This information came out about the clinical trial
According to the information, the first and second clinical trials of BBV-154 Intranasal Vaccine were conducted. During this, the vaccine was given as the first and second doses. After successful testing, it was also tested as a booster dose. However, the booster dose was given to those people who had taken both the doses of Covid. According to reports, the data of both the human clinical trials of Phase III have been sent to the National Regulatory Authority for approval. Several levels were tested during the first dose trial. During this, every aspect of safety and immunogenicity was carefully checked.
Tests were done at 14 places across the country
Bharat Biotech conducted tests at 14 places across India. The BBV154 vaccine has been shown to be safe, tolerable, and immune-boosting in trials. This nasal vaccine (Nasal Corona Vaccine) has been developed by Bharat Biotech International Ltd. has prepared. The company had said that the vaccine dose given to healthy volunteers in the first phase of clinical trials worked well and no serious adverse events were reported. The vaccine was found to be safe, immunogenic and well-functioning in pre-clinical toxicity studies.